Evidence map›Paper›PMID 24282525›Full record

ArticlePloS one2013

RABL6A, a novel RAB-like protein, controls centrosome amplification and chromosome instability in primary fibroblasts.

Xuefeng Zhang, Jussara Hagen, Viviane P Muniz, Tarik Smith, Gary S Coombs, Christine M Eischen, Duncan I Mackie, David L Roman, Richard Van Rheeden, Benjamin Darbro and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020
    Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Xuefeng ZhangDepartment of Pharmacology, University of Iowa, Iowa City, Iowa, United States of America.
Jussara Hagen
Viviane P Muniz
Tarik Smith
Gary S Coombs
Christine M Eischen
Duncan I Mackie
David L Roman
Richard Van Rheeden
Benjamin Darbro
Van S Tompkins
Dawn E Quelle
University of Iowa · USVanderbilt University Medical Center · USWaldorf College · US

Funding

Growth Inhibition by the ARF Tumor SuppressorR01CA090367 · NCI · UNIVERSITY OF IOWA · PI QUELLE, DAWN E · 2002 to 2011
$2.9M
Novel Suppressors of Pancreatic CancerR21CA127031 · NCI · UNIVERSITY OF IOWA · PI QUELLE, DAWN E · 2009 to 2010
$363k
NCI NIH HHS CA090367NCI NIH HHS CA127031NCI NIH HHS R01 CA090367NCI NIH HHS R21 CA127031
6 · The paper itself

Abstract

RABL6A (RAB-like 6 isoform A) is a novel protein that was originally identified based on its association with the Alternative Reading Frame (ARF) tumor suppressor. ARF acts through multiple p53-dependent and p53-independent pathways to prevent cancer. How RABL6A functions, to what extent it depends on ARF and p53 activity, and its importance in normal cell biology are entirely unknown. We examined the biological consequences of RABL6A silencing in primary mouse embryo fibroblasts (MEFs) that express or lack ARF, p53 or both proteins. We found that RABL6A depletion caused centrosome amplification, aneuploidy and multinucleation in MEFs regardless of ARF and p53 status. The centrosome amplification in RABL6A depleted p53-/- MEFs resulted from centrosome reduplication via Cdk2-mediated hyperphosphorylation of nucleophosmin (NPM) at threonine-199. Thus, RABL6A prevents centrosome amplification through an ARF/p53-independent mechanism that restricts NPM-T199 phosphorylation. These findings demonstrate an essential role for RABL6A in centrosome regulation and maintenance of chromosome stability in non-transformed cells, key processes that ensure genomic integrity and prevent tumorigenesis.

Indexed as

ADP-Ribosylation FactorsAnimalsCentrosomeChromosomal InstabilityFibroblastsGene Knockout TechniquesGene SilencingHumansMiceNuclear ProteinsNucleophosminOncogene Proteinsrab GTP-Binding ProteinsTumor Suppressor Protein p53ADP-Ribosylation FactorsNPM1 protein, humanNuclear ProteinsNucleophosminOncogene Proteinsrab GTP-Binding ProteinsRABL6A protein, humanRABL6A protein, mouseTumor Suppressor Protein p53

Identifiers

PMID24282525
PMCPMC3839920
OpenAlexW2086015182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.